TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

doi:10.1002/ijc.70434

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

International journal of cancer - 15 Jun 2026

Fountzilas Christos, Rosario Spencer, Witkiewicz Agnieszka K, Withers Henry G, Bajor David L, Mukherjee Sarbajit, Saltzman Joel, Maguire Orla, Minderman Hans, Chatley Sarah, Tarquini Mary Lynn, Whitworth Amy, Jurcevic Jennifer, Hsiao Hua-Hsin, Knudsen Erik S, Muhitch Jason B, Abrams Scott I, Kalinski Pawel, Segal Brahm H, Bakin Andrei, Yuan Guangwei, Wang Chong, Attwood Kristopher, Iyer Renuka, Boland Patrick M

Abstract excerpt

Immunotherapy with checkpoint inhibitors targeting the PD1/PD-L1 and CTLA4 pathways has limited activity in patients with microsatellite stable (MSS) colorectal adenocarcinoma (CRC). In a prior study, the combination of cetuximab and pembrolizumab failed to improve outcomes for patients with advanced RAS wild-type (RASwt) CRC. In this post hoc secondary analysis, we show that the cetuximab and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Progression-Free Survival

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41793309
DOI: 10.1002/ijc.70434
PMCID: PMC13019156

Genes

TP53
CTLA4
IL6
LAG3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.PMID 41793309Read ↗

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant.Semantic proximity Read ↗

Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients.Semantic proximity Read ↗

Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer?Semantic proximity Read ↗

The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal CancerSemantic proximity Read ↗

The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications.Semantic proximity Read ↗

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.Semantic proximity Read ↗

Prognostic Impact of RAS and TP53 Mutation Profiles in Metastatic Colorectal Cancer.Semantic proximity Read ↗

RAS mutation status and immune microenvironment define distinct prognostic landscapes and predict chemotherapy benefit in pMMR colorectal cancer.Semantic proximity Read ↗

Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.Semantic proximity Read ↗

Cancer type-dependent correlations between TP53 mutations and antitumor immunity.Semantic proximity Read ↗

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.Semantic proximity Read ↗

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.